Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aclidinium bromide 100 μg · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Aclidinium bromide 100 μg bid | EXPERIMENTAL | Aclidininum bromide 100 μg twice daily by inhalation |
| Aclidininum bromide 200 μg bid | EXPERIMENTAL | Aclidininum bromide 200 μg twice daily by inhalation |
| Aclidininum bromide 400 μg bid | EXPERIMENTAL | Aclidininum bromide 400 μg twice daily by inhalation |
| Placebo | PLACEBO_COMPARATOR | Placebo twice-daily by inhalation |
| Formoterol 12 μg bid | ACTIVE_COMPARATOR | Formoterol 12 μg twice daily by inhalation |
| Name | Type | Description |
|---|---|---|
| Aclidinium bromide 100 μg bid | DRUG | Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days |
| Aclidinium bromide 200 μg bid | DRUG | Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days |
| Aclidininum bromide 400 μg bid | DRUG | Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days |
| Placebo | DRUG | Placebo via inhalation in the morning and evening for 7 days |
| Formoterol 12 μg bid | DRUG | Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days |
Inclusion Criteria: 1. Males and non-pregnant, non-lactating females aged ≥ 40. 2. Patients with a clinical diagnosis of stable moderate to severe COPD, according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines: (http://www.goldcopd.com) and stable airway obstruction...
Aclidinium bromide 100 μg is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is a long-acting muscarinic antagonist that is administered via inhalation to help manage symptoms of COPD.
Aclidinium bromide 100 μg is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN.
Aclidinium bromide 100 μg is currently in Phase 2 of clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied for its efficacy and safety in patients with COPD.
Aclidinium bromide 100 μg has been studied in one completed Phase 2 clinical trial, identified by the National Clinical Trial number NCT01120093. This trial evaluated the efficacy and safety of three doses of aclidinium bromide compared to placebo and an active comparator in patients with COPD.
Yes, Aclidinium bromide 100 μg is a specific dose of the drug aclidinium bromide. The 100 μg formulation is being investigated as a potential treatment for COPD, and it is the dose that was evaluated in the Phase 2 clinical trial.